Last October I posted two updates on small cell lung cancer (SCLC). One explored the broad SCLC landscape, while the second was a detailed analysis highlighting the red and green flags to watch out for in the Rova-T TRINITY study.
My sombre conclusion or prediction, if you will, was not particularly well received at that time:
“My sense is that the median PFS and OS in the allcomer ITT population will remain modest and in line with what we might expect from historical chemos in 3L SCLC.”
This morning AbbVie announced that they will not be filing for accelerated approval of Rova-T in 3L SCLC based on the interim analysis. In other words my expectations for this trial were met, although there are many who will be very disappointed at the results.
What matters though is not just how disappointing topline results might be per se, but why they occurred, what we can do about it, and most importantly, where we go next. There’s a lot more to this than might initially be obvious from the press release.
That’s what this new post is all about… first a post mortem, then the obstacles to be addressed, and finally, what we can look forward to in SCLC…
On a happier note: there may be some surprises ahead!